Prevention of transfusion-transmitted cytomegalovirus infection

Transfusion Medicine

Volumn 9, Issue 2, 1999, Pages 115-123

  Pamphilon, D H ^a   Rider, J R ^a   Barbara, J A J ^a   Williamson, L M ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood transfusion; Cytomegalovirus; Leucodepletion

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

BLOOD; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DISEASE TRANSMISSION; GENETICS; HUMAN; IMMUNOLOGY; LEUKOCYTE; REVIEW; VIROLOGY;

ANTIBODIES, VIRAL; BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HUMANS; LEUKOCYTES;

EID: 0033152917     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.1999.00193.x     Document Type: Review

References (60)

1. AABB. (1997) Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV). American Association of Blood Banks, Association Bulletin, 97-2, 10-12.
2. Anon. (1997) Blood Products Advisory Committee meeting, 19 September, 1997. The effect of leukoreduction on CMV transmission through blood transfusion. USA Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research.
3. Anon. (1996) Guidelines for the Blood Transfusion Services in the United Kingdom, 3rd edn. HMSO, London.
4. Bitsch, A., Kirchner, H., Dupke, R. & Bein, G. (1992) Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion, 32, 612-617.
5. Boeckh, M., Gooley, T.A., Myerson, D., Cunningham, T., Schoch, G. & Bowden, R.A. (1996) Cytomegalovirus pp65 antigenemia-guided early treatment with ginciclovir versus ganciclovir at engraftment after allogenic marrow transplantation: a randomized double-blind study. Blood, 88, 4063-4071.
6. Boivin, G., Handfield, J., Toma, E., Murray, G., Lalonde, R., Tevere, V.J., Sun, R. & Bergeron, M.G. (1998) Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. Journal of Clinical Microbiology, 36, 2509-2513.
7. Bowden, R.A., Fisher, L.D., Rogers, K., Cays, M. & Meyers, J.D. (1991) Cytomegalovirus (CMV) -specific intravenous © 1999 Blackwell Science Ltd, Transfusion Medicine, 9, 115-123 immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. Journal of Infectious Diseases, 164, 483-487.
8. Bowden, R.A. & Sayers, M. (1990) The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion, 30, 762-763.
9. Bowden, R.A., Sayers, M.H., Cays, M. & Slichter, S.J. (1989) The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion, 29 (Suppl. 1), 57S.
10. Bowden, R.A., Sayers, M.H., Flournoy, N., Newton, B., Banaji, M., Thomas, E.D. & Meyers, J.D. (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. New England Journal of Medicine, 314, 1006-1010.
11. Bowden, R.A., Slichter, S.J., Sayers, M., Weisdorf, D., Cays, M., Schoch, G., Banaji, M., Haake, R., Welk, K., Fisher, L., McCullough, J. & Miller, W. (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood, 86, 3598-3603.
12. Bowden, R.A., Slichter, S., Sayers, M., Weisdorf, D. & Fisher, L. (1996) Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Response. Blood, 87, 4910-4911.
13. Doern, G.V., Robbie, L. & Marrama, L. (1994) Comparison of two enzyme immunoassays and two latex agglutination assays for detection of cytomegalovirus antibody. Diagnosis of Microbiological Infectious Diseases, 20, 109-112.
14. Eisenfeld, L., Silver, H., McLaughlin, J., Klevjer-Anderson, P., Mayo, D., Anderson, J., Herson, V., Krause, P., Savidakis, J., Lazar, A., Rosenkrantz T. & Pisciotto P. (1992) Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion, 32, 205-209.
15. Foot, A.B., Pamphilon, D., Caul, E.O., Roome, A.P., Hunt, L.P., Cornish, J.M. & Oakhill, A. (1998) Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts. British Journal of Haematology, 102, 671-677.
16. Fowler, K.B., Stagno, S., Pass, R.F., Britt, W.J., Boll, T.J. & Alford, C.A. (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New England Journal of Medicine, 326, 663-667.
17. Gilbert, G.L., Hayes, K., Hudson, I.L. & James, J. (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet, i, 1228-1231.
18. Goodnough, L.T., Riddell, J., Lazarus, H., Chafel, T.L., Prince, G., Hendrix, D. & Yomtovian, R. (1993) Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sanguinis, 65, 103-107.
19. de Graan Hentzen, Y.C., Gratama, J.W., Mudde, G.C., Verdonck, L.F., Houbiers, J.G., Brand, A., Sebens, F.W., van Loon, A.M., The, T.H. & Willemze, R. (1989) Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion, 29, 757-760.
20. Greijer, A.E., van de Crommert, J.M., Stevens, S.J. & Middeldorp, J.M. (1999) Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays. Journal of Clinical Microbiology, 37, 179-188.
21. Grillner, L. (1987) Screening of blood donors for cytomegalovirus (CMV) antibodies: an evaluation of different tests. Journal of Virological Methods, 17, 133-139.
22. Hebart, H. & Einsele, H. (1998) Diagnosis and treatment of cytomegalovirus infection. Current Opinions in Hematology, 5, 483-487.
23. Hillyer, C.D., Emmens, R.K., Zago-Novaretti, M. & Berkman, E.M. (1994) Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion, 34, 929-934.
24. Hillyer, C.D., Lankford, K.V., Roback, J.D., Gillespie, T.W. & Silberstein, L.E. (1999) Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6, 7 and 8. Transfusion Medicine Reviews, 13, 1-17.
25. Hodinka, R.L. (1998) The clinical utility of viral quantitation using molecular methods. Clinical and Diagnostic Virology, 10, 25-47.
26. James, D.J., Sikotra, S., Sivakumaran, M., Wood, J.K., Revill, J.A., Bullen, V. & Myint, S. (1997) The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transfusion Medicine, 7, 123-126.
27. de Jong, M.D., Galasso, G.J., Gazzard, B., Griffiths, P.D., Jabs, D.A., Kern, E.R. & Spector, S.A. (1998) Summary of the II International Symposium on Cytomegalovirus. Antiviral Research, 39, 141-162.
28. Kondo, K., Kaneshima, H. & Mocarski, E.S. (1994) Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proceedings of the National Academy of Sciences, USA, 91, 11879-11883.
29. Krajden, M., Shankaran, P., Bourke, C. & Lau, W. (1996) Detection of cytomegalovirus in blood donors by PCR using the digene SHARP signal system assay: effects of sample preparation and detection methodology. Journal of Clinical Microbiology, 34, 29-33.
30. Landaw, E.M., Kanter, M. & Petz, L.D. (1996) Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood, 87, 4910-4911.
31. Larsson, S., Söderberg-Nauclér, C. & Möller, E. (1998a) Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals: implications for prevention of CMV transmission. Transplantation, 65, 411-415.
32. Larsson, S., Söderberg-Nauclér, C., Wang, F.-Z. & Möller, E. (1998b) Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion, 38, 271-278.
33. Lau, W., Onizuka, R. & Krajden, M. (1998) Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line. Journal of Clinical Virology, B11B, 109-116.
34. Lipson, S.M., Toro, A., Lotlikar, M., Match, M.E., Kaplan, M.H., Shepp, D.H. & Gong, J. (1997) Significance of leukocyte concentration in the performance of the quantitative cytomegalovirus (CMV) antigenemia assay. Clinical Diagnostic Virology, 8, 151-158.
35. Logan, S., Barbara, J. & Kovar, I. (1988) Cytomegalovirus screened blood for neonatal intensive care units. Archives of Disease in Childhood, 63, 753-755.
36. Manfredi, R., Lazzarotto, T., Spezzacatena, P., Dal Monte, P., Mastroianni, A., Corondo, O.V. & Chiodo, F. (1997) Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease. Journal of Antimicrobial Chemotherapy, 40, 299-302.
37. van der Meer, J.T., Drew, W.L., Bowden, R.A., Galasso, G.J., Griffiths, P.D., Jabs, D.A., Katlama, C., Spector, S.A. & Whitley, R.J. (1996) Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis of Cytomegalovirus. Antiviral Research, 32, 119-140.
38. Miller, W.J., McCullough, J., Balfour, H.H. Jr, Haaker, R.J., Ramsey, N.K., Goldman, A., Bowman, R. & Kersey, I. (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: a randomised trial of blood product screening. Bone Marrow Transplantation, 7, 227-234.
39. Movassagh, M., Gozlan, J., Senechal, B., Baillou, C., Petit, J.C. & Lemoine, F.M. (1996) Direct infection of CD34+ progenitor cells by human cytomegalovirus: Evidence for inhibition of hematopoiesis and viral replication. Blood, 88, 1277-1283.
40. Murphy, M.F., Grint, P.C., Hardiman, A.E., Lister, T.A. & Waters, A.H. (1988) Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. British Journal of Haematology, 70, 253-254.
41. Narvios, A.B., Przepiorka, D., Tarrand, J., Chan, K.W., Champlin, R. & Lichtiger, B. (1998) Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplantation, 22, 575-577.
42. Novotny, V.M., van Doorn, R., Witvliet, M.D., Claas, F.H. & Brand, A. (1995) Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood, 85, 1736-1741.
43. Pamphilon, D.H., Foot, A.B.M., Adeodu, A., Steward, C.G., Cornish, J.M., Marks, D.I. & Oakhill, A. (1999) Prophylaxis and prevention of CMV infection in BM allograft recipients: Leucodepleted platelets are equivalent to those from CMV seronegative donors. Bone Marrow Transplantation, 23, (Suppl. 1), S66.
44. Persons, D.L., Moore, J.A. & Fishback, J.L. (1991) Comparison of polymerase chain reaction, DNA hybridization, and histology with viral culture to detect cytomegalovirus in immunosuppressed patients. Modern Pathology, 4, 149-153.
45. van Prooijen, H.C., Visser, J.J., van Oostendorp, W., de Gast, G.C. & Verdonck, L.F. (1994) Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. British Journal of Haematology, 87, 144-147.
46. Riddell, S.R. & Greenberg, P.D. (1997) T cell therapy of human CMV and EBV infection in immunocompromised hosts. Reviews of Medical Virology, 7, 181-192.
47. Roth, W.K., Weber, M. & Seifried, E. (1999) Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood bank setting. Lancet, 353, 359-363.
48. Seropian, S., Ferguson, D., Salloum, E., Cooper, D. & Landry, M.L. (1998) Lack of reactivity to CMV pp. 65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplantion, 22, 507-509.
49. Sinclair, J. & Sissons, P. (1996) Latent and persistent infections of monocytes and macrophages. Intervirology, 39, 293-301.
50. Soderberg-Naucler, C., Fish, K.N. & Nelson, J.A. (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 91, 119-126.
51. Steffens, H.P., Kurz, S., Holtappels, R. & Reddehase, M.J. (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. Journal of Virology, 72, 1797-1804.
52. The Trial to Reduce Alloimmunisation to Platelets Study Group. (1997) Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New England Journal of Medicine, 337, 1861-1869.
53. Urushibara, N., Kwon, K.W., Takahashi, T.A. & Sekiguchi, S. (1995) Human cytomegalovirus DNA is not detectable with nested double polymerase chain reaction in healthy blood donors. Vox Sanguinis, 68, 9-14.
54. Verdonck, L.F., Graan-Hentzen, Y.C., Dekker, A.W., Mudde, G.C. & de Gast, G.C (1987) Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplantation, 2, 73-78.
55. Walter, E.A., Greenberg, P.D., Gilbert, N.J., Finch, R.J., Watanabe, K.S., Thomas, E.D. & Riddell, S.R. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine, 333, 1038-1044.
56. Wielaard, F., Scherders, J., Dagelinckx, C., Hooijmans, A., Smit-Siebinga, C.T. & Welle, F. (1986) Development of CMV antibody tests and their clinical evaluation. Vox Sanguinis, 51, 31-34.
57. Williamson, L.M., Wimperis, J.Z., Williamson, P., Copplestone, J.A., Gooi, H.C., Morgernstern, G.R. & Norfolk, D.R. (1994) Bedside filtration of blood products in the prevention of HLA alloimmunisation - a prospective randomised study. Blood, 83, 3028-3035.
58. de Witte, T., Schattenberg, A., van Dijk, B.A., Galama, J., Olthuis, H., van der Meer, J.W. & Kunst, V.A. (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation, 59, 964-968.
59. Zhang, L.J., Hanff, P., Rutherford, C., Churchill, W.H. & Crumpacker, C.S. (1995) Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. Journal of Infectious Diseases, 171, 1002-1006.
60. Zhuravskaya, T., Maciejewski, J.P., Netski, D.M., Bruening, E., Mackintosh, F.R. & St Jeor., S. (1997) Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells: model of HCMV latency. Blood, 90, 2482-2491.